Syndax Pharmaceuticals, Inc. (SNDX)

NASDAQ • Healthcare

$20.56

-$0.12 (-0.6%)

Market closed

Last close at September 4, 2026 at 20:00 UTC

Day Range$20.46 - $21

Avg. Volume (3M)1.2M

Market Cap$1.8B

52 Week Range

$12.99$25.59

Next EarningsIn 58 daysNov 2, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$72.7M100%

Gross Profitminus cost of goods$69.5M96%

In plain terms: out of every $100 in revenue, Syndax Pharmaceuticals, Inc. currently loses $68.

Fundamentals & Financials

Revenue (TTM)

$252M

Net Income (TTM)

-$220.7M

EPS (TTM)

-$2.52

ROA (TTM)

-31.37%

Current Ratio

6.77

Dividend Yield

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+17.0%Q3 2025-$0.83

+5.4%Q4 2025-$0.7

-33.6%Q1 2026-$0.78

+18.6%Q2 2026-$0.48

-22.9%Q3 2026-$0.55

Nov 2

in 58 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

View full earnings history

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc. is a NASDAQ-listed biotechnology company developing cancer therapies, with a clinical-stage pipeline centered on targeted and immune-mediated treatments. In FY2025, it generated $172.4 million in revenue. Its main programs are SNDX-5613 for certain acute leukemias, SNDX-6352 for chronic graft versus host disease, and entinostat.

Name

Syndax Pharmaceuticals, Inc.

CEO

Michael A. Metzger

Website

www.syndax.com

Industry

Healthcare

Year Founded

2005

Employees

298

Today's Snapshot

AI-generated

The day ended with SNDX 0.6% lower at 20.56, in line with a weaker sector. Syndax Pharmaceuticals gave 19 employees rights to buy up to 175,000 shares over four years.

Trading Volume

Below 10d avg (1.3M)

1.1M

vs S&P 500 Today

Moderate Underperformance

-0.16%

Updated: September 4, 2026 at 20:13 UTC

Technical Indicators

5 Buy2 Neutral1 Sell

SNDX carries a buy bias with the price around 20.56 and a modest trend reading (ADX ~22). Short-term averages sit at or below the current price and CCI and short-momentum readings are positive, while RSI and MACD are essentially neutral; stochastic is elevated and signals caution. Intraday volatility is muted with ATR near 4.1%, yet on-balance volume is negative, indicating distribution despite constructive moving-average alignment. The classic pivot at 20.74 is a nearby level to watch. Technical takeaway: Buy.

All signals

EMA (5 indicators)$20.01 - $20.50
Buy
RSI (14)53.47
Neutral
Stochastic %K (14, 3, 3)83.97
Sell
MACD Level (12, 26)-0.02
Neutral

Peers & Related Assets

RLAYRelay Therapeutics, Inc.

$19.04+0.2%

AMLXAmylyx Pharmaceuticals, Inc.

$34.1+0.4%

INBXInhibrx Biosciences Inc.

$121.17-0.9%

ORICORIC Pharmaceuticals, Inc.

$12.86+0.9%

SANASana Biotechnology, Inc.

$3.85-1.8%

ATAIAtai Beckley Inc.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.